Register to get free articles
Want unlimited access? View Plans
Already have an account? Sign in
Interpath Advisory has appointed value creation specialist Jayshree (Jay) Shah to lead the firm’s support for Healthcare and Life Sciences businesses.
The firm said the announcement comes as it continues to invest in its growing Advisory practice.
Shah joins from FTI, where she was the EMEA Healthcare and Life Sciences sector lead in the Corporate Finance and Restructuring practice.
She has over 20 years of experience in working with both Corporate and Private Equity clients. Her experience covers a range of advisory services, including value creation, commercial and operational pre-deal diligence, business transformation, accelerated operational cost reduction, carve-outs and post-deal integration.
As well as working for PwC and EY in their operational deal advisory teams, Shah is Association of the British Pharmaceutical industry (ABPI) qualified and has “extensive hands-on” Pharmaceutical and Healthcare industry experience working in-house in the industry, including roles at Schering Plough (MSD), Datamonitor Pharma and Amdipharm (now Advanz Pharma).
Prior to FTI, she was appointed European Strategy leader at a NASDAQ listed digital interactions company Conduent, where she was responsible for driving growth in the European footprint through a corporate and go-to-market strategy across four key verticals.
In addition, Interpath has appointed Robbie McFaul as a director in its Transactions Services team. He joins after nearly 11 years with PwC where he specialised in transactions within the healthcare, pharmaceutical, technology, media and telecommunications sectors.
Based out of Interpath’s Leeds office, he will support managing director Louise Smith, who joined the firm from EY in October 2023.
Commenting on her appointment, Shah said: “Joining Interpath provides me with an excellent opportunity to pursue my passion and to make a real difference to organisations in the Healthcare and Life sciences sector. I’m able to build a team with autonomy that’s not conflicted and draws on specialists from across its multi-disciplinary capabilities to deliver meaningful value for clients.
“I’m also focused on further expanding our Value Creation team itself as part of Interpath’s thriving Advisory practice. The pressure has never been greater for investors to create value and have impact which puts at the heart of the M&A market as we support across the deal cycle.”
McFaul said: “I’ve been impressed by the scale that Interpath and its Deal Advisory team have already achieved, but also the thriving entrepreneurial culture and multi-disciplinary model. It is an exciting place to be and the perfect moment to join as we build a proposition that really challenges the market for the benefit of corporates, investors, and business owners. It is a privilege to join Louise and her team and can’t wait to get stuck in at such a critical period in the regional dealmaking market.”
Mark Raddan, head of Advisory at Interpath, added: “With each appointment, we’re making major strides forward as we build out our Advisory practice. We have market-leading professionals across a full suite of services and these appointments are further evidence of our commitment to invest, bring in the best talent and demonstrates our ambition for further growth.
“Jay is an exceptional talent in the Pharmaceutical and wider Healthcare and Life Sciences industry and will lead our engagement for what is an incredibly important sector for the UK economy and M&A market. With Jay’s extensive transaction and value creation experience, and Robbie’s work over the past decade in transaction services, we’re adding even more depth to our already thriving advisory offering.”
